Short conversational transcript (YouTube #shorts) featuring Robert Whitfield MD and another speaker discussing how GLP‑1 drugs dramatically change eating behavior, reduce type 2 diabetes incidence, and likely reduce dialysis demand; speakers link these clinical effects to large financial shifts (fast food and dialysis industries, Wall Street). The tone is conversational and speculative about long‑term market impacts.
Chapters
So I would say if the drug Companies knew what GLP1s were are doing now, they would have never let them be proofed. Because think about what they're doing and you follow the money trail, which you just have to be very plain about this. Wall street has moved money out of fast food and dialysis centers because you're going to see the ramifications of these drugs long term is one, a big decrease in diabetes typ to and two, because of that, a big decrease in dialysis. So those are two huge money. Right? So, well.
It'S like they, they went for the short term win instead of the long term one. Right. You got a lifelong patient with dialysis or you get the money quick now and it became the number one drug in sold in the world. Right.
Because for your audience, what these drugs do is they modify behavior. No drug in history has done it this effectively. You take that drug, you don't even care about eating. So the amount of people in the line at Waterburger in Texas or McDonald's in Scottsdale has gone way down.
And you can get it through insurance.
Yes. Right. So 100% they're just kicking themselves in board meetings all the time.
